Early results of clinical trials of co-agonists of glucagon and its related receptors (GLP-1R and glucose-dependent insulinotropic peptide receptor) as treatments for MASLD are promising (American Diabetes Association 2023, Boehringer Ingelheim 2024). Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.